SpringWorks Therapeutics, Inc.
Clinical trials sponsored by SpringWorks Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing targeted therapies for rare diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver function and drug breakdown: a new study on mirdametinib Results expected Oct 2026 (estimated)
- New pill targets Hard-to-Treat cancers with hippo pathway mutations Results expected Jan 2027 (estimated)
- New pill shows promise for rare tumor in japanese patients Results expected May 2027 (estimated)
-
New drug shows promise for rare ovarian cancer in early trial
Disease control CompletedThis phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how m…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a pill stop desmoid tumors from growing?
Disease control CompletedThis phase 3 trial investigates whether nirogacestat, an oral drug, can slow the growth of desmoid tumors (also called aggressive fibromatosis) in adults whose tumors are progressing. Half the participants receive nirogacestat, while the other half receive a placebo, in a double-…
Phase 3 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Healthy volunteers help uncover drug interaction secrets
Knowledge-focused CompletedThis study looked at how a common seizure medicine, carbamazepine, changes the amount of mirdametinib in the blood. 36 healthy adults took both drugs by mouth. The goal was to understand how the body processes mirdametinib when taken with carbamazepine, which can help doctors dec…
Phase 1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Heartburn pills may change how this drug works
Knowledge-focused CompletedThis study looked at how two common heartburn medications, famotidine and rabeprazole, affect the levels of nirogacestat in the blood of 24 healthy men. Participants took nirogacestat alone and with each heartburn drug to see if the combination changes how much medicine gets into…
Phase 1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Healthy men needed to test drug interaction risks
Knowledge-focused CompletedThis study looks at whether the drug nirogacestat affects how the body breaks down other common medications. Twenty healthy men will take nirogacestat along with a mix of five other drugs to measure any changes. The goal is to understand safety and dosing, not to treat any diseas…
Phase 1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC